Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TECX Stock Forecast 2025-2026
$20.01
Current Price
$372.83M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TECX Price Targets
+404.7%
To High Target of $101.00
+279.8%
To Median Target of $76.00
+219.8%
To Low Target of $64.00
TECX Price Momentum
+5.2%
1 Week Change
+3.6%
1 Month Change
-59.7%
1 Year Change
-56.7%
Year-to-Date Change
-67.2%
From 52W High of $61.07
+46.1%
From 52W Low of $13.70
📊 TOP ANALYST CALLS
Did TECX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tectonic Therapeutics is one of their latest high-conviction picks.
Latest TECX Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, TECX has a bullish consensus with a median price target of $76.00 (ranging from $64.00 to $101.00). The overall analyst rating is N/A (N/A/10). Currently trading at $20.01, the median forecast implies a 279.8% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tiago Fauth at Wells Fargo, projecting a 404.7% upside. Conversely, the most conservative target is provided by Danielle Brill at Truist Securities, suggesting a 219.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TECX Analyst Ratings
8
Buy
0
Hold
0
Sell
TECX Price Target Range
Low
$64.00
Average
$76.00
High
$101.00
Current: $20.01
Latest TECX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TECX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 3, 2025 | Oppenheimer | Leland Gershell | Outperform | Initiates | $80.00 |
| Jul 21, 2025 | Truist Securities | Danielle Brill | Buy | Initiates | $64.00 |
| Jun 11, 2025 | Raymond James | Michael Freeman | Outperform | Reinstates | $76.00 |
| Jun 6, 2025 | LifeSci Capital | Outperform | Initiates | $87.00 | |
| May 15, 2025 | Mizuho | Uy Ear | Outperform | Maintains | $85.00 |
| Apr 21, 2025 | Mizuho | Uy Ear | Outperform | Initiates | $51.00 |
| Mar 21, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $101.00 |
| Jan 31, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $112.00 |
| Nov 20, 2024 | Raymond James | Danielle Brill | Outperform | Initiates | $65.00 |
| Nov 12, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $79.00 |
| Nov 11, 2024 | Leerink Partners | David Risinger | Outperform | Maintains | $69.00 |
| Aug 22, 2024 | Wells Fargo | Tiago Fauth | Overweight | Initiates | $55.00 |
| Jul 24, 2024 | Leerink Partners | David Risinger | Outperform | Initiates | $49.00 |
| Jun 26, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Initiates | $76.00 |
| Jun 24, 2024 | TD Cowen | Tyler Van Buren | Buy | Initiates | $N/A |
Tectonic Therapeutic Inc. (TECX) Competitors
The following stocks are similar to Tectonic Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Tectonic Therapeutic Inc. (TECX) Financial Data
Tectonic Therapeutic Inc. has a market capitalization of $372.83M with a P/E ratio of 4.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -32.2%.
Valuation Metrics
Market Cap
$372.83M
Enterprise Value
$105.63M
P/E Ratio
4.6x
PEG Ratio
-0.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+71.7%
Current Ratio
29.2x
Debt/Equity
0.5x
ROE
-32.2%
ROA
-21.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tectonic Therapeutic Inc. (TECX) Business Model
About Tectonic Therapeutic Inc.
What They Do
Biopharmaceutical company developing transformative therapies.
Business Model
Tectonic Therapeutic operates by discovering and developing innovative drugs that target complex diseases with unmet medical needs. The company utilizes advanced technology platforms to create precision medicine therapies, allowing it to generate revenue through partnerships, research collaborations, and potential product sales.
Additional Information
The company is influential in the biotechnology and healthcare sectors, collaborating with research institutions and industry partners to enhance its therapeutic programs. Tectonic Therapeutic's commitment to innovation positions it as a significant player in the evolving medical biotechnology landscape, attracting attention from stakeholders and investors.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
51
CEO
Dr. Alise S. Reicin M.D., Ph.D.
Country
United States
IPO Year
2018
Website
tectonictx.comTectonic Therapeutic Inc. (TECX) Latest News & Analysis
Latest News
Quick Summary
Tectonic Therapeutic reported positive phase 1b results for PH-HFrEF. It is pursuing phase 2 APEX for CpcPH, with topline data expected in 2026. The company has $268.4 million to fund operations through Q4 2028.
Why It Matters
Tectonic Therapeutics' positive trial results and strong cash position enhance its growth potential, attracting investor interest in upcoming clinical milestones and expansion plans.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Tectonic Therapeutics reported positive topline results from its Phase Ib Part B trial of TX45 for patients with PH-HFrEF on October 29, 2025.
Why It Matters
Positive trial results for Tectonic Therapeutic's TX45 could indicate potential market approval and future revenue growth, impacting stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Tectonic Therapeutic (NASDAQ: TECX) reported positive Phase 1b results for TX45, showing it was well tolerated and improved heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEF.
Why It Matters
Positive Phase 1b results for TX45 signal potential for a new treatment in a specific heart condition, enhancing Tectonic's market position and likely boosting investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tectonic Therapeutic, Inc. (NASDAQ: TECX) will participate in three investor conferences in September 2025, focusing on therapeutic proteins and GPCRs.
Why It Matters
Tectonic Therapeutic's participation in investor conferences signals potential growth and investor engagement, crucial for funding and market perception in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Tectonic (TECX) Q2 R&D Soars 142%
4 months ago
Quick Summary
Tectonic Therapeutic (TECX) reported a Q2 2025 net loss of $20 million, or $(1.07) per share, exceeding analysts' expectations of $(0.98) per share.
Why It Matters
Tectonic Therapeutic's larger-than-expected net loss signals potential challenges in financial performance, possibly affecting investor confidence and stock valuation.
Source: The Motley Fool
Market Sentiment:
Positive
Tectonic Therapeutic Joins Russell 3000® Index
5 months ago
Quick Summary
Tectonic Therapeutic, Inc. (NASDAQ: TECX) has been added to the Russell 3000® Index, effective June 30, 2025, following the annual reconstitution of the Russell US Indexes.
Why It Matters
Tectonic Therapeutic's inclusion in the Russell 3000 Index enhances its visibility and liquidity, potentially attracting more institutional investors and boosting its stock price.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TECX Stock
What is Tectonic Therapeutic Inc.'s (TECX) stock forecast for 2026?
Based on our analysis of 9 Wall Street analysts, Tectonic Therapeutic Inc. (TECX) has a median price target of $76.00. The highest price target is $101.00 and the lowest is $64.00.
Is TECX stock a good investment in 2026?
According to current analyst ratings, TECX has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TECX stock?
Wall Street analysts predict TECX stock could reach $76.00 in the next 12 months. This represents a 279.8% increase from the current price of $20.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tectonic Therapeutic Inc.'s business model?
Tectonic Therapeutic operates by discovering and developing innovative drugs that target complex diseases with unmet medical needs. The company utilizes advanced technology platforms to create precision medicine therapies, allowing it to generate revenue through partnerships, research collaborations, and potential product sales.
What is the highest forecasted price for TECX Tectonic Therapeutic Inc.?
The highest price target for TECX is $101.00 from Tiago Fauth at Wells Fargo, which represents a 404.7% increase from the current price of $20.01.
What is the lowest forecasted price for TECX Tectonic Therapeutic Inc.?
The lowest price target for TECX is $64.00 from Danielle Brill at Truist Securities, which represents a 219.8% increase from the current price of $20.01.
What is the overall TECX consensus from analysts for Tectonic Therapeutic Inc.?
The overall analyst consensus for TECX is bullish. Out of 9 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $76.00.
How accurate are TECX stock price projections?
Stock price projections, including those for Tectonic Therapeutic Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 9, 2025 4:06 AM UTC